STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch

STAT PlusBiotech The biotech scorecard for the third quarter: 15 stock-moving events to watch Trial readouts from Amylyx Pharmaceuticals, Biogen, and other companies Manage alerts for this article Email this article Share this article By Adam FeuersteinJuly 1, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx Pharmaceuticals: Results from the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia, a rare metabolic condition that causes severe drops in blood sugar. Advertisement Biogen: In May, the company announced results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease called diranersen that targets the protein tau. Detailed data from the study will be presented on July 14 at the Alzheimer’s Association International Conference. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Biotech June 30, 2026 STAT Plus: AI company Anthropic announces it will begin developing drugs of its own Biotech June 30, 2026 STAT Plus: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry Advertisement The Readout June 30, 2026 STAT Plus: Investors double down on Bain-backed startup Health Tech Newsletter June 30, 2026 STAT Plus: FDA digital leader hints at coming AI policy updates Biotech June 30, 2026 STAT Plus: Abivax seeks to ease safety concerns with new data, boosting shares Subscriber Picks